KING OF PRUSSIA, PA--(Marketwired - February 08, 2017) - Genomind, a personalized medicine company advancing mental healthcare through genetic testing, has completed an $11 million financing with its ...
CHALFONT, PA--(Marketwired - September 23, 2013) - Genomind, a personalized medicine company in neuropsychiatry, is excited to announce the launch of their new clinician portal. The new Genomind ...
Genomind, a King of Prussia-based mental health company, and NeuroFlow, a Philadelphia-based health care analytics and technology company, recently announced an agreement to partner their proprietary ...
A breakthrough in the translation of genetic mechanisms and traits that can influence a person’s behavioral predispositions, Genomind Mental Health Map provides the starting point to empower consumers ...
February 16, 2012 – Boston, MA – Genomind today announced that the Massachusetts General Hospital (MGH) Department of Psychiatry is beginning a major inpatient study examining the use of genetic ...
Genomind’s new CORE Anxiety and Depression Report is the most advanced and comprehensive depression and anxiety-focused service available in the mental health PGx market. It analyzes 15 genes that ...
“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email qmuse@phillymag.com ...
KING OF PRUSSIA, PA--(Marketwired - January 09, 2017) - In 2016, more Americans underwent genetic testing performed by Genomind (www.genomind.com) to help guide treatment of mental illness than in any ...
KING OF PRUSSIA, Pa. and ATLANTA, Dec. 9, 2019 /PRNewswire/ -- Genomind®, the leading mental health company, and Sharecare, the digital health company that helps people manage all their health in one ...
CHALFONT, PA--(Marketwired - October 22, 2013) - Genomind, a personalized medicine company, is pleased to announce their participation at the American Academy of Child & Adolescent Psychiatry (AACAP) ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The partnership will expand access to Genomind's Genecept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results